Literature DB >> 2738620

Adjuvant chemotherapy for head and neck cancer.

C Jacobs1.   

Abstract

Entities:  

Mesh：

Year:  1989        PMID： 2738620     DOI： 10.1200/JCO.1989.7.7.823

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

Review 1.  Has chemotherapy proved itself in head and neck cancer?

Authors:  J S Tobias
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

Review 2.  Current role of chemotherapy in head and neck cancer.

Authors:  J S Tobias
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

3.  Synergistic interaction between cisplatin and tamoxifen delays the emergence of cisplatin resistance in head and neck cancer cell lines.

Authors:  B Nakata; K D Albright; R M Barton; S B Howell; G Los
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Selective intra-arterial infusion of high-dose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formation.

Authors:  G Los; f A Blommaert; R Barton; D D Heath; L den Engelse; C Hanchett; D Vicario; R Weisman; K T Robbins; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 5.  Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer.

Authors:  Kevin J Cullen; Zejia Yang; Lisa Schumaker; Zhongmin Guo
Journal:  J Bioenerg Biomembr       Date:  2007-02       Impact factor: 3.853
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.